Previous 10 | Next 10 |
Gelesis’ six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., “Categorical”) and the change in...
New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat “western-like” diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain Pu...
PureTech press release (NASDAQ:PRTC): FY Revenue of $17.39M (+47.7% Y/Y). Strong capital base with cash and cash equivalents of $418.9M and consolidated cash and cash equivalents of $465.7M as of December 31, 2021 For further details see: PureTech reports FY results
Strong capital base with PureTech level cash and cash equivalents of $418.9 million 1 and consolidated cash and cash equivalents of $465.7 million 2 as of December 31, 2021 Rapidly progressing pipeline of 27 therapeutics and therapeutic candidates, across Wholly Owned ...
Full Phase 1 data analysis of VE303, a defined bacterial consortium candidate for C. difficile infection, published in Cell Host & Microbe Positive topline Phase 2 results for VE303 announced in 2021; Phase 3 preparations underway Acceptance of three abstracts ...
AKL-T03 showed a statistically significant improvement in sustained attention compared to control intervention AKL-T03 is built on the same technology engine as Akili’s digital therapeutic EndeavorRx, which has been cleared by the U.S. Food and Drug Administration (FDA)...
Bioavailability of buprenorphine up to 20-fold higher in preclinical models using prodrug generated with the Glyph technology, driven by transport of prodrug through the gut-draining lymphatics The research published in Frontiers in Pharmacology further demonstrates the ab...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Tuesday, April 26, 2022 at 2:00 AM EDT / 7:00 AM BST. The report will include the Company’s financial results for the year ended December 31...
Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...
Seasoned life sciences expert brings further global portfolio management and financial expertise from 20 years at Merck & Co. Inc. to the PureTech board Ms. Barber-Lui will also become chair of the Audit Committee of the board PureTech Health plc (Nasdaq: PRT...
News, Short Squeeze, Breakout and More Instantly...
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated...
2024-06-27 14:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, confirms that the Tender Offer announced by the Company on 20 May 2024 is now ...